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ABSTRACT   
Objective: To identify characteristics of pediatric sickle cell disease (SCD) hospitalizations, and to 
examine admission demographics and medical expenditures. 
 Methods: Admissions with SCD were identified from the 2009 and 2012 releases of the Healthcare 
and Cost Utilization Project’s Kids Inpatient Database. Disease-specific secondary diagnoses 
including; acute chest syndrome (ACS), vaso-occlusive pain crisis (VOC), splenic sequestration, and 
stroke/transient ischemic attack were analyzed for patient and hospital demographics. Analytical 
endpoints included total healthcare expenditures and mortality.  
Results: We reviewed 75,234 inpatient hospitalizations with a diagnosis of SCD.  Over $900,000,000 
was spent annually in associated healthcare expenditure. The median length of hospitalization stay 
(LOS) for all admissions was 3 days (IQR 2-5 days). VOC was the most frequent secondary 
diagnosis, recording 48,698 total hospitalizations and a median LOS of 3 days (IQR 2-6 days). Of the 
8,490 hospitalizations with ACS, the infant population had a significantly higher mortality rate 
compared to other age groups (2% vs. 0.3%, p < 0.001). Cerebral vascular accidents incurred the 
second highest median hospitalization cost ($18,956), behind ACS ($22,631). A high proportion of 
Caucasian patients died during hospitalization for VOC (0.4% vs 0.1%, p=0.014) and ACS (4% vs 
0.2%, p < 0.001) when compared to non-Caucasians.  
 Conclusion: Inpatient hospitalizations for secondary manifestations of pediatric SCD were 
associated with significant healthcare expenditures.  Patients with an increased statistical risk for 
death during hospitalization included Caucasians with SCD complications of ACS and VOC, and 
patients <1-year-old with ACS. Further research is needed to substantiate the associated clinical 
significance of these findings. 
Key Words: pediatric sickle cell disease, Kid’s Inpatient Database, length of stay, hospitalization 
costs 
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INTRODUCTION 
Sickle cell disease (SCD) is an autosomal recessive genetic defect in hemoglobin 
1
, with 
approximate incidences as high as 1 in 365 persons in the Black U.S. population.
2
 Disease 
manifestations can include pain crisis, splenic sequestration, acute chest syndrome (ACS), and 
cerebrovascular accidents (CVA). These conditions are largely the result of a mechanistically similar 
vaso-occlusive phenomena,
1,3
 yet the morbidity, mortality, and healthcare expenditure associated with 
each presentation differs greatly. The National Institutes of Health has dedicated over one quarter of a 
billion dollars in recent years (2007-2013) to basic science and clinical research efforts targeting 
treatment and prevention modalities within this disorder.
4
 
In 2010, Brousseau and colleagues reported sickle cell vaso-occlusive crisis (VOC) was the 
leading cause of hospital utilization for SCD patients.
5
 They found demographic and socioeconomic 
factors including age and insurance payer type to modify one’s frequency of hospitalization and 
incidence of 30 day rehospitalization.  Two related publications reported similar trends in 
hospitalization and incidence.
6,7
 Despite significant scientific inquiry into SCD incidence and 
associated healthcare expenditures, there remains a lack of population based investigation into factors 
contributing to one’s length of hospitalization stay (LOS), and outcome analysis, including death.  
The population-based, database approach we have employed affords statistical power in analyzing 
SCD hospitalizations in low incidence groups, as well as providing better aggregate perspectives to 
already well-studied populations. In the United States, progressive social advancements and 
generations of immigration have created a vibrant, melting-pot population. With this comes a variety 
of genetic diseases that are being seen in a more diverse group of patients. In Europe, immigration en 
masse is a more recent phenomenon than in the U.S. and its effects are already being seen in 
hemoglobinopathies and SCD epidemiology.
8,9 As a result, reporting on traditionally understudied 
groups has added utility in the modern world. Although not often reported in the U.S., A New York 
newborn screening program estimates Caucasian (non-Hispanic) SCD incidences as low as 1: 40,000 
births.
10
 Large patient sample sizes possible through large databases are required for adequate power 
to analyze these hospitalizations. .  
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Our analysis aimed to identify populations with high risk complications and the expenditures 
associated with those complications. Furthermore, our analysis of admissions with SCD stands to not 
only direct therapy in communities with heavy disease burden, such as Black and Hispanic American 
communities, but also shed light on populations with lower incidences of SCD that are not typically 
studied.  
METHODS 
We reviewed inpatient records from 2009 and 2012 of the Kids Inpatient Database (KID).
11
 The 
KID is maintained by the Agency for Healthcare Research and Quality’s Healthcare Cost and 
Utilization Project, and contains information about patient and hospital characteristics for roughly 
80% of hospitalizations for children (< 21 years) in the United States.  The database includes 
admissions from approximately 4,100 U.S. hospitals in 44 of the 50 states. Historically new releases 
of the KID have occurred every 3 years, with versions of the KID prior to 2016 used ICD-9 coding, 
while subsequent versions used ICD-10. Our study, utilizing the 2009 and 2012 databases represents a 
comprehensive analysis with one coding scheme (ICD-9). Several recent publications have used the 
KID in a similar manner to characterize other pediatric conditions.
12-14
 
Admissions with SCD were identified within the KID by queries of ICD-9 diagnosis codes 282.62 
(Hb-SS Disease with crisis), 282.61 (Hb-SS Disease without crisis) and 282.60 (Sickle Cell Anemia 
NOS). Admissions with potential disease-specific SCD diagnoses (ACS, VOC, CVA, splenic 
sequestration) were identified by ICD-9 codes, with patient demographic and hospitalization 
characteristics characterized. Admission sample weights provided by the KID were used to adjust the 
roughly 80% cohort of American hospitalizations into a validated nationwide estimation. Endpoints 
included patient age, race, gender, billable charges excluding physician fees, death, and length of 
hospitalization (LOS). Charges from 2009 were adjusted for inflation by utilizing US Department of 
Commerce Bureau of Economic Analysis website coefficients to match 2012 costs. Our study 
qualified as non-identifiable human subject research employing the use of publicly available data, and 
thus was exempted from IRB approval.  
Statistical Analysis 
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Data were grouped for analysis using SPSS statistical software version 23 (Armonk, NY: IBM 
Corp) and Microsoft Excel (Seattle, WA). Medians and interquartile ranges (IQR) were used to 
describe the distribution of data for LOS and charges per admission. A multivariate binary logistic 
regression analysis was conducted to explore independent predictors contributing to mortality 
(mortality vs. no mortality) during SCD hospitalization. ANOVA analyses were run to compare 
continuous samples where applicable, with a threshold for statistical significance set at p < 0.05.  
RESULTS 
A total of 75,234 hospitalizations reporting a diagnosis of SCD were collectively reported in 2009 
and 2012 (Table 1). Of these hospitalizations, 70.1% and 87.3% were from urban teaching hospitals 
in 2009 and 2012, respectively—with approximately only 3.5% from rural hospitals during each of 
the two years. Annual healthcare expenditure for SCD admissions totaled over $900,000,000, with a 
median hospitalization cost of $14,337 per stay. Black patients accounted for a majority of admissions 
(81.6%) with Hispanics (4.6%) and Caucasians (1.6%.) totaling substantially smaller cohorts. 
Individuals between 16-20 years old accounted for 38.4% of hospitalizations for SCD.   
The overall mortality associated with any inpatient hospitalization was 0.1%. Multi-variate 
analysis (Table 2) demonstrated that a diagnosis of congenital heart disease (p < 0.001), sepsis (p < 
0.001), stroke (p < 0.001), and ACS (p < 0.001) all carried statistical predilection for increased risk of 
patient death during these pediatric hospitalizations.   
Acute Chest Syndrome 
Overall, there were 8,490 hospitalizations recording a diagnosis of acute chest syndrome (ACS) 
(Table 1). The median length of hospitalization in this cohort was 4 days (IQR range 3-7 days), with 
median hospitalization charges $22,631 per admission. Figures 1a and 1b depict incidence and length 
of stay by age grouping respectively. Twenty-five patients (0.3%) admitted with ACS died during 
their hospitalization. Table 3 details rates of mortality in ACS; as displayed, patients <1-year-old had 
a statistically significant higher risk of death (p <0.001). Also, a statistically significant greater 
proportion of Caucasian patients (3.8%) died during hospitalization when compared to mortality from 
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SCD in other racial and ethnic groups (p <0.001). Collectively, hospitalizations for ACS averaged 
$24,115,994 in annual expenditures. 
Vaso-Occlusive Crisis 
VOC accounted for 48,698 hospitalizations, the highest subtotal over the two-year period of study 
(Table 1), with nearly half (47.6%) of the hospitalizations in patients aged 16-20 years (Figure 1c). 
Caucasian admissions contributed to only 1.4% of the VOC cohort, however these patients carried a 
statistically significant increased risk of death during their hospitalization, (0.4%, p = 0.020) (Table 
3). In all, 47 patients (0.1%) with a diagnosed VOC died during their inpatient stay. Collectively, 
hospitalizations for vaso-occlusive crises averaged $189,863,407 in annual expenditures. 
Splenic Sequestration 
Splenic Sequestration was most commonly identified in admissions of patients <5 years in age 
(72.4%) (Table 1)(Figure 2a). Length of stay trended towards longer hospitalizations as age 
increased (Figure 2b). Death was an uncommon occurrence, and was witnessed in < 0.1% of 
hospitalizations for splenic sequestration. Collectively, hospitalizations for splenic sequestration 
averaged $6,621,818 in annual expenditures. 
Cerebrovascular Accident  
In total, 3,669 cerebrovascular events occurred during SCD hospitalizations (Table 1). Incidence 
increased with age (Figure 2c). A graph identifying median length of stay by age group revealed 
longer hospitalizations for older patients as well. (Figure 2d). No age cohort carried a statistically 
significant predilection for death following a cerebrovascular event (Table 3). Overall, 20 patients 
(0.5%) died during an admission associated with a CVA or TIA. Collectively, hospitalizations for 
CVA in pediatric SCD totaled $11,592,354 in expenditures yearly. 
DISCUSSION 
        Investigation of the cost, length of stay, and mortality of SCD hospitalizations and its 
complications can provide useful context to clinical presentation. As with other database studies, our 
results rely on the accuracy of medical chart reporting of demographics, an important caveat that is 
discussed further in the limitations. Despite that, our study encompasses one of the largest current 
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collections of SCD patients and enables adequate power for analysis of understudied patient 
populations. We found that Caucasian patients had increased rates of mortality during hospitalizations 
for ACS or VOC. Despite widespread newborn screening in the U.S.,
15
 SCD may be under recognized 
in the non-Black population, especially if patients have immigrated to the U.S. after the newborn 
period. From a practical standpoint, the absolute mortality (n=4) in the Caucasian SCD demographic 
limited any definitive clinical conclusions. Finally, we must consider that the KID may have 
inaccurately categorized patients by racial or ethnic group, especially in situations involving biracial 
children. Further study of SCD-related mortality in non-Black populations may help substantiate these 
findings.  
With regards to ACS, the significantly higher mortality we report in infant admissions may be due 
to the relatively non-specific criteria for ACS (fever, increased work of breathing, new infiltrate on 
chest x-ray, decline of respiratory status, etc.). This may lead to under recognition, and misdiagnosis 
of ACS for less severe clinical entities such as pneumonia or bronchiolitis. A recent report proposes 
that monitoring the rate of respiratory decline can help ensure a more accurate diagnosis of ACS.
16
 
Heightened vigilance and the refinement of ACS diagnostic criteria may curtail mortality in this this 
high-risk age group. 
VOC hospitalizations accounted for over half of the total hospitalizations, and were more common 
in older pediatric age groups. These findings support a similar analysis of KID data from 1997 where 
LOS also increased with age.
7
  This highlights an ever-present clinical scenario suggesting that age 
may be a reliable predictor of a patient’s LOS or episodic severity. We suspect that recognition of this 
clinical trend may allow for streamlining measures to decrease hospital expenditure and patient 
suffering by encouraging early and adequate pain management strategies. However, it seems that the 
unfortunate incorporeal nature of an individual’s pain, in combination with recent initiatives to 
decrease opioid medication use may still leave practitioners hesitant to adequately manage a patient’s 
VOC pain crisis. Emergency department (ED) providers may have a bias towards pain medication 
addiction when it comes to sickle cell related pain.
17
 African-Americans with SCD have been shown 
to have 25% longer ED wait times compared to other patient populations, suggesting that racial 
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disparities may impact time to medical care.
18
  Nonetheless, this hesitancy towards swift care and 
analgesia in the ED might allow pain crises to advance to levels more difficult to manage, further 
increasing LOS and costs.   
In line with prior literature, we found that patients admitted for splenic sequestration most 
commonly were within the youngest population of patients analyzed (0-5 years). In a cohort of 190 
patients with SCD diagnosed at birth, the median age of the first episode of acute splenic 
sequestration crisis occurred at 1.4 years.
19
 Moreover, these same patients experienced 437 episodes 
of splenic sequestration collectively with 67% of these patients experiencing more than one episode.
19
 
In our analysis, the incidence of splenic sequestration hospitalizations also decreased as patients grew 
older. This is likely explained by the notion that the probability of sequestration decreases as the 
amount of functional splenic tissue decreases in older patients through repeated tissue infarctions. Up 
to 90% of SCD patients aged 5 years old have functional or anatomical asplenia.
20
 Also noteworthy, 
patient mortality from splenic sequestration was low (< 0.1%) in our sample. However, older reports 
from a sickle cell cohort study with 216 patients from 1981 had mortality rates as high as 12% within 
the first episode.
21
 The decline we see in mortality rates between our data and older reports over the 
last 35 years may be due to implementation of more widespread newborn screening, patient 
education, transfusion programs and prophylactic splenectomies.
22
   
The mortality rate for CVA was the highest of the four diagnoses, while median costs ranked 
second highest. This result illustrates the clinical and economic impact that a stroke diagnosis carries 
in patients with SCD. For such reasons, primary stroke prevention strategies have been becoming 
more popular. A recent systematic review and cost-effectiveness analysis concluded that use of 
transcranial doppler (TCD) ultrasonography for identifying children with high risk for stroke and 
prophylactic blood transfusions appeared to be both clinically effective and cost-effective when 
compared to screening with TCD ultrasonography alone.
23
 Other studies have shown that hydroxyurea 
therapy is another cost-effective option for secondary stroke prevention in children with SCD, 
especially in resource constrained countries.
24
 Newer investigations from the TWiTCH trial have 
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shown that hydroxyurea therapy can decrease TCD velocities, which may be an indicator of reduced 
stroke risk in pediatric SCD patients.
25
  
Such innovative prevention strategies are starting to change the age distribution of stroke diagnosis 
in patients with SCD. When looking at a pediatric subset (ages 0-20) from a prospective, multi-center 
study which enrolled 4082 patients from the years 1978 to 1988, there was a peak incidence of stroke 
between ages of 2-9.
26
 However, our data shows that SCD hospitalizations with stroke was far more 
common in the 10-20 age range, with a peak in the 19-year-old age group. We hypothesize that such a 
shift in age preference during the last few decades could largely be a result of prevention strategies 
and close monitoring earlier in a patient’s life. However, as a patient ages, the financial burden and 
time-commitment required to manage SCD becomes sizeable. These patients may be lost to follow 
up, rendering prevention strategies difficult to implement, effectively delaying CVA incidence rather 
than reducing it. The time-intensive nature of SCD in children is highlighted by reports that claim 
these students miss up to 10% of the average school year.
27
 Thus, there may be a necessity to 
implement programs to help alleviate the inconveniences that are associated with frequent sickle cell 
care (e.g. driving long distances to hospitals with sickle cell programs). While some effective 
programs already exist,
28
 more focus on this matter may help recapture patients lost to follow up for 
these reasons.  
Although our study encompasses one of the largest cohorts of pediatric SCD hospitalizations 
available and identifies key demographical discrepancies of care, the resources incorporated into our 
analysis carry a few important limitations worthy of remark. Primarily, KID data uses hospital 
discharge paperwork, and relies on the accuracy of reported admission characteristics. Specifically, 
patient race is a difficult analysis to validate from hospital level discharge as patient demographics 
may not be self-reported.
29,30
 Yet, the more often a patient presents to a healthcare system (e.g. 
hospitalizations), there is greater agreement between patient self-reported race/ethnicity data and 
administrative recording of race/ethnicity (e.g. medical chart data).
29
 In other words, there are more 
opportunities to record accurate demographic data. From this we can reasonably surmise that the SCD 
admission demographics from the KID database, are more likely to be accurate since SCD patients 
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frequently visit healthcare systems (e.g. emergency department visits, hospitalizations, etc.).
31
 
Secondly, databases such as the KID contain only admission-level data and frequently do not provide 
information about treatment modalities or patient history for context. Therefore, this impacts the 
applicability of some of our findings.  Finally, without patient identifiers to examine one’s severity of 
disease it becomes difficult to identify whether a small subset of patient’s greatly impacts expenditure 
and resource utilization in SCD. However, by including over 70,000 hospitalizations, from over 4,000 
hospitals nationwide, the quantity of data analyzed provides an aggregate hospitalization depiction 
that still provides utility from an epidemiological perspective. Typically, large database studies such 
as this offer a broad complement to more clinically focused intra-institutional studies where case-
specific data is more robust, but likely underpowered.  
In conclusion, the data presented here highlights pediatric SCD mortality and related patient 
demographics. Additionally, SCD and its common complications are associated with considerable 
aggregate and admission-level expenditures. Hospitalizations with ACS and VOC in Caucasian 
populations are associated with statistically significant higher mortality rates, as are infants with ACS. 
Further studies may more closely characterize these discrepancies.  
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FIGURE LEGENDS 
 
 
Figure 1 A-D Acute Chest Syndrome (ACS) (A, B) and Vaso-Occlusive Crisis (C, D): Total number 
of hospitalizations stratified by age group (A, C) and Median Length of Inpatient Admission (LOS) 
(B, D) by Age Group.  
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Figure 2 A-D Splenic Sequestration (Splenic) (A, B) and Stroke (C, D): Total number of 
hospitalizations stratified by age group (A, C) and Median Length of Stay (LOS) (B, D) by Age 
Group. 
 
Table 1: Database Characteristics 
 Admissions 
(%) 
ACS (%) Vaso-
Occlusive 
(%) 
Splenic (%) Stroke (%) 
No. 75,234 8,490 48,698 1,881 3,669 
Ages      
<1 4,022 (5.3) 137 (1.6) 830 (1.7) 237 (12.9) --- 
1-5 15,957 
(21.2) 
1,978 
(23.3) 
7,312 
(15.0) 
1,089 
(59.5) 
197 (4.6) 
6-10 12,321 
(16.4) 
2,165 
(25.5) 
7,595 
(15.6) 
265 (14.5) 534 (14.5) 
11-15 13,925 
(18.5) 
1,698 
(20.2) 
9,684 
(19.9) 
139 (7.6) 898 (24.5) 
16-20 28,897 
(38.4) 
2,505 
(29.5) 
23,193 
(47.6) 
98 (5.3) 2060 (56.1) 
O/NR 112 (0.1) --- 84 (0.2) --- --- 
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Sex      
Male 37,661 
(50.1) 
4,754 
(56.0) 
24,033 
(49.4) 
996 (54.4) 1813 (49.4) 
Female 37,452 
(49.8) 
3,729 
(43.9) 
24,585 
(50.5) 
839 (45.6) 1856 (50.6) 
Race      
Caucasian 1,124 (1.6) 107 (1.3) 664 (1.4) 36 (2.0) 31 (0.9) 
Black 61,366 
(81.6) 
6,843 
(80.6) 
40,614 
(83.4) 
1,370 
(74.8) 
3012 (82.1) 
Hispanic 3,428 (4.6) 400 (4.7) 2,091 (4.3) 150 (8.2) 181 (4.9) 
Asian 177 (0.2) 32 (0.4) 103 (0.2) 11 (0.6) 10 (0.3) 
O/NR 9,038 
(12.0) 
1,108 
(13.1) 
5,225 
(10.7) 
263 (14.4) 434 (11.8) 
LOS (IQR) 3 (2-5) 4 (3-7) 3 (2-6) 3 (2-4) 3 (2-6) 
Charges 
($) 
14,337 22,631 15,566 14,858 18,956 
(IQR) (8,314-
25,620) 
(13,314-
41,190) 
(9,139-
27,726) 
(9,065-
27,098) 
(10,785-
35,100) 
Death 91 (0.1) 25 (0.3) 47 (0.1) --- 20 (0.5) 
ACS – Acute chest syndrome, Splenic – Splenic sequestration, Stroke – Stroke/TIA, O/NR – other/not 
recorded during hospitalization, LOS – Length of hospitalization (days), IQR – Interquartile Range, --- 
too few patients to report national incidence estimation, LOS and Charges reported as median with 
IQR 
 
Table 2: Multivariate Analysis: Mortality by  Diagnosis/Characteristic Regression Outputs 
 Odds Ratio 95% CI for Odds 
Ratio 
Sig. 
SCD Related    
Sepsis 44.6 28.8 – 69.2 < 0.001 
CVA 3.7 2.2 – 6.3 < 0.001 
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ACS 3.4 2.1 – 5.7 < 0.001 
Splenic 
Sequestration 
1.1 0.2 – 6.2 0.916 
Vaso-occlusive 
pain 
0.4 0.3 – 0.7 < 0.001 
Non-SCD Related    
CHD 15.5 4.1 – 58.5 < 0.001 
Obesity 1.9 0.5 – 7.1 0.327 
OSA 1.3 0.4 – 4.8 0.678 
Asthma 0.7 0.4 – 1.2 0.225 
Dehydration 0.3 0.1 – 1.3 0.100 
DM 0.0 0.0 – 0.0 0.994 
Other 
Characteristics 
   
Gender 1.2 0.8 – 1.8 0.380 
Teaching Hospital 1.1 0.6 – 1.8 0.744 
Non-Black 0.8 0.4 – 1.4 0.440 
Age < 5 0.4 0.2 – 0.8 0.006 
Constant   < 0.001 
CVA=cerebral vascular accident, ACS = acute chest syndrome, CHD=congenital heart disease OSA = 
obstructive sleep apnea, DM = diabetes mellitus, Odds Ratio reflects death incidence in conjunction 
with comorbid diagnosis, Gender represents male sex 
Table 3: 2009 and 2012 Inpatient Mortality 
 ACS Vaso-Occlusive Stroke/TIA 
N 25 47 20 
Ages    
<1 2.0% 
p<0.001 0.0% 
p=0.233
 0.0% 
p=0.907
 
1-5 0.0% <0.1% 0.9% 
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6-10 0.4% 0.1% 0.3% 
11-15 0.1% 0.1% 0.7% 
16-20 0.5% 0.1% 0.5% 
Sex    
Male 0.2% 
p=0.638 0.1% 
p= 0.831 0.6% 
p=0.778 
Female 0.4% 0.1% 0.5% 
Race    
Caucasian 3.8% 
p<0.001 0.4% 
p=0.020 0.0% 
p=0.361 
Black 0.2% 0.1% 0.7% 
Hispanic 0.0% 0.2% 0.0% 
Asian 0.0% 0.0% 0.0% 
O/NR 0.4% <0.1% 0.0% 
ACS – Acute chest syndrome, O/NR – other/not recorded during hospitalization, statistical analysis 
exponents compare death rates by cohort - i.e. % of males vs. females that died during 
hospitalization, percentages represent proportions for a given cohort 
 
 
 
